Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | CNR2 | P34972 | 13/20 | 0.70 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.66 |
| ▸ | CNR1 | P21554 | 10/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29988803 | 0.87 | CNR2 (0.66) | LMNACNR2PTPN7CNR1HDAC1 | |
| SCHEMBL29988288 | 0.84 | CNR2 (0.76) | CNR2CNR1 | |
| SCHEMBL11903673 | 0.83 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL31052987 | 0.83 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL29388144 | 0.82 | CNR2 (1.00) | LMNACNR2CNR1 | |
| SCHEMBL20552905 | 0.82 | CNR2 (1.00) | LMNACNR2CNR1 | |
| SCHEMBL8960050 | 0.81 | CNR2 (0.61) | LMNACNR2CNR1HDAC1 | |
| SCHEMBL30641112 | 0.80 | CNR2 (0.94) | CNR2CNR1 | |
| SCHEMBL16173737 | 0.80 | CNR1 (0.80) | CNR2CNR1 | |
| SCHEMBL29683703 | 0.80 | CNR1 (0.80) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| CN-120001345-A | Application of magnetic cyclodextrin metal organic framework polymer in enrichment and detection of synthetic cannabinoids | 中国药科大学 | 2025-05-16 | — | — | CN | claimed |
| EP-3664795-B1 | CANNABIS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN AND INFLAMMATION RELATED WITH DENTAL PULP AND BONE REGENERATION RELATED TO DENTAL JAW BONE DEFECTS | CANNIBITE BVBA (BE) | 2024-06-19 | — | — | EP | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| CN-120001345-A | Application of magnetic cyclodextrin metal organic framework polymer in enrichment and detection of synthetic cannabinoids | 中国药科大学 | 2025-05-16 | — | — | CN | disclosed |
| EP-3664795-B1 | CANNABIS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN AND INFLAMMATION RELATED WITH DENTAL PULP AND BONE REGENERATION RELATED TO DENTAL JAW BONE DEFECTS | CANNIBITE BVBA (BE) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024020572-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PTSD | NEW YORK STEM CELL FOUNDATION, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
| CN-116297923-A | Rapid identification method for indole and indazole type synthetic cannabinoid novel psychoactive substance structure | 广西大学 | 2023-06-23 | — | — | CN | disclosed |
| US-11612581-B2 | Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects | CANNIBITE BVBA | 2023-03-28 | — | — | US | disclosed |
| WO-2022217147-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | ROSENFELD MARK J (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | LMNA 1269/4885CNR2 204/4885PTPN7 2308/4885 |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | LMNA 3037/4885CNR2 2/4885PTPN7 3959/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | LMNA 3441/4885CNR2 1/4885PTPN7 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.